相似文献
1
Neuroleukemiosis Masquerading as Drug Toxicity in an Adolescent With Refractory AML.
Am J Hematol. 2025 Oct;100(10):1853-1858. doi: 10.1002/ajh.70006. Epub 2025 Jul 23.
2
Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
Blood. 2024 Apr 11;143(15):1513-1527. doi: 10.1182/blood.2023021105.
3
Targeting the Menin-KMT2A interaction in leukemia: Lessons learned and future directions.
Int J Cancer. 2025 Jan 30. doi: 10.1002/ijc.35332.
4
Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in -Rearranged Acute Lymphoblastic and Myeloid Leukemia.
Int J Mol Sci. 2024 May 30;25(11):6020. doi: 10.3390/ijms25116020.
5
Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias.
Blood. 2024 Sep 12;144(11):1206-1220. doi: 10.1182/blood.2023022480.
6
Advances in menin inhibition in acute myeloid leukemia.
Trends Cancer. 2025 Jul 3. doi: 10.1016/j.trecan.2025.06.002.
7
Menin inhibitors in KMT2A-rearranged and NPM1-mutated acute leukemia: A scoping review of safety and efficacy.
Crit Rev Oncol Hematol. 2025 Sep;213:104783. doi: 10.1016/j.critrevonc.2025.104783. Epub 2025 May 27.
8
Therapeutic Implications of Menin Inhibitors in the Treatment of Acute Leukemia: A Critical Review.
Diseases. 2025 Jul 19;13(7):227. doi: 10.3390/diseases13070227.
9
Menin inhibitors in KMT2A-rearranged leukemia: Mechanistic insights, clinical trial progress, and potential of combination therapies.
Leuk Res. 2025 Oct;157:107924. doi: 10.1016/j.leukres.2025.107924. Epub 2025 Jul 28.
10
Targeting the undruggable: menin inhibitors ante portas.
J Cancer Res Clin Oncol. 2023 Sep;149(11):9451-9459. doi: 10.1007/s00432-023-04752-9. Epub 2023 Apr 27.
本文引用的文献
1
Menin Inhibition With Revumenib for -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
J Clin Oncol. 2025 Jan;43(1):75-84. doi: 10.1200/JCO.24.00826. Epub 2024 Aug 9.
2
How I treat refractory and relapsed acute myeloid leukemia.
Blood. 2024 Jan 4;143(1):11-20. doi: 10.1182/blood.2023022481.
3
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.
Nature. 2023 Mar;615(7954):920-924. doi: 10.1038/s41586-023-05812-3. Epub 2023 Mar 15.
4
Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium.
Pediatr Blood Cancer. 2022 Oct;69(10):e29812. doi: 10.1002/pbc.29812. Epub 2022 Jun 21.
5
Neurologic complications of acute myeloid leukemia. Diagnostic approach and therapeutic modalities.
Blood Rev. 2022 May;53:100910. doi: 10.1016/j.blre.2021.100910. Epub 2021 Nov 20.
6
Drug-related demyelinating syndromes: understanding risk factors, pathophysiological mechanisms and magnetic resonance imaging findings.
Mult Scler Relat Disord. 2021 Oct;55:103146. doi: 10.1016/j.msard.2021.103146. Epub 2021 Jul 21.
7
Peripheral nerve disease secondary to systemic conditions in children.
Ther Adv Neurol Disord. 2019 Aug 12;12:1756286419866367. doi: 10.1177/1756286419866367. eCollection 2019.
8
Neuroleukemiosis: Diagnosis and management.
Clin Neurol Neurosurg. 2019 Sep;184:105340. doi: 10.1016/j.clineuro.2019.04.019. Epub 2019 Apr 17.
9
Palliative Care as a Standard of Care in Pediatric Oncology.
Pediatr Blood Cancer. 2015 Dec;62 Suppl 5(Suppl 5):S829-33. doi: 10.1002/pbc.25695.
10
Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities.
Clin Cancer Res. 2016 Feb 1;22(3):553-9. doi: 10.1158/1078-0432.CCR-15-0339. Epub 2015 Aug 31.
Zotero 插件